Pulmonary Delivery of Peptides and Proteins

Peptide and Protein Delivery

Volumn , Issue , 2011, Pages 23-46

  Lip Kwok, Philip Chi ^a   Chan, Hak Kim ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882499572     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-384935-9.10002-1     Document Type: Chapter

References (113)

1. M.K. Campbell (1999) Biochemistry. Orlando, USA: Harcourt Brace & Company
2. P.S. Bailey Jr. and C.A. Bailey (1995) Organic Chemistry: A Brief Survey of Concepts and Applications. Upper Saddle River, NJ, USA: Prentice-Hall International
3. D. Crommelin, E. van Winden and A. Mekking (2002) Delivery of pharmaceutical proteins. M.E. Aulton (Eds) Pharmaceutics: The Science of Dosage Form Design Edinburgh, UK: Churchill Livingstone 544-553.
4. R.J. Altiere and D.C. Thompson (2007) Physiology and pharmacology of the airways. A.J. Hickey (Eds) Inhalation Aerosols: Physical and Biological Basis for Therapy New York, USA: Informa Healthcare USA
5. R.K. Wolff (1998) Safety of inhaled proteins for therapeutic use. J. Aerosol Med. 11 197-219.
6. J.R. Wright (1990) Clearance and recycling of pulmonary surfactant. Am. J. Physiol.-Lung Cell. Mol. Physiol. 259 L1-L12.
7. W.C. Hinds (1999) Aerosol Technology. New York, USA: John Willey & Sons
8. A. Hayem, A. Scharfman, A. Laine, J.J. Lafitte and B. Sablonniere (1980) Proteases and antiproteases in brochoalveolar lavage. Bull. Eur. Physiopathol. Respir. (Suppl. 6), 247-260.
9. A. Janoff, L. Raju and R. Dearing (1983) Levels of elastase activity in bronchoalveolar lavage fluids of healthy smokers and nonsmokers. Am. Rev. Respir. Dis. 127 540-544.
10. S.F. Smith, A. Guz, N.T. Cooke, G.H. Burton and T.D. Tetley (1985) Extracellular elastolytic activity in human lung lavage: A comparative study between smokers and non-smokers. Clin. Sci. 69 17-27.
11. J. Fujita, N.L. Nelson, D.M. Daughton, C.A. Dobry, J.R. Spurzem, S. Irino, et al. (1990) Evaluation of elastase and antielastase balance in patients with chronic bronchitis and pulmonary emphysema. Am. Rev. Respir. Dis. 142 57-62.
12. M. Orlowski, J. Orlowski, M. Lesser and K.H. Kilburn (1981) Proteolytic enzymes in bronchopulmonary lavage fluids: Cathepsin B-like activity and prolyl endopeptidase. J. Lab. Clin. Med. 97 467-476.
13. D.B. Borson (1991) Roles of neutral endopeptidases in airways. Am. J. Physiol.-Lung Cell. Mol. Physiol. 260 L212-L225.
14. J.W. Ryan (1989) Peptidase enzymes of the pulmonary vascular surface. Am. J. Physiol.-Lung Cell. Mol. Physiol. 257 L53-L60.
15. A.R. Johnson, J. Ashton, W.W. Schultz, E.G. Erdös, Neutral metalloendopeptidase in human lung tissue and cultured cells. Am. Rev. Respir. Dis. 132 (1985) 564–568.
16. D.A. Wall and A.T. Lanutti (1993) High levels of exopeptidase activity are present in rat and canine bronchoalveolar lavage fluid. Int. J. Pharm. 97 171-181.
17. A. Janoff (1985) Elastases and emphysema. Am. Rev. Respir. Dis. 132 417-433.
18. S.A. Adibi and E.L. Morse (1971) Intestinal transport of dipeptides in man: Relative importance of hydrolysis and intact absorption. J. Clin. Invest. 50 2266-2275.
19. R.E. Stratford Jr. and V.H.L. Lee (1986) Aminopeptidase activity in homogenates of various absorptive mucosae m the albino rabbit: Implications in peptide delivery. Int. J. Pharm. 30 73-82.
20. G.H. Caughey (1992) Peptide metabolism by lung and airway peptidases. J. Biopharm. Sci. 3 233-240.
21. J.S. Patton, S. Nagarajan and A. Clark (1998) Pulmonary absorption and metabolism of peptides and proteins. R.N. Dalby, P.R. Byron, S.J. Farr (Eds) Respiratory Drug Delivery VI Bufflao Grove, IL, USA: Interpharm Press 17-24.
22. S. Onoue, N. Hashimoto and S. Yamada (2008) Dry powder inhalation systems for pulmonary delivery of therapeutic peptides and proteins. Expert Opin. Ther. Patents 18 429-442.
23. U.B. Kompella and V.H.L. Lee (1992) (C) Means to enhance penetration: (4) Delivery systems for penetration enhancement of peptide and protein drugs: Design considerations. Adv. Drug Deliv. Rev. 8 115-162.
24. D. Deshpande, D. Toledo-Velasquez, L.Y. Wang, C.J. Malanga, J.K.H. Ma and Y. Rojanasakul (1994) Receptor-mediated peptide delivery in pulmonary epithelial monolayers. Pharm. Res. 11 1121-1126.
25. D.A. Groneberg, M. Nickolaus, J. Springer, F. Döring, H. Daniel and F. Axel (2001) Localization of the peptide transporter PEPT2 in the lung: Implications for pulmonary oligopeptide uptake. Am. J. Pathol. 158 707-714.
26. A.N.O. Dodoo, S. Bansal, D.J. Barlow, F.C. Bennet, R.C. Hider, A.B. Lansley, et al. (2000) Systematic investigations of the influence of molecular structure on the transport of peptides across cultured alveolar cell monolayers. Pharm. Res. 17 7-14.
27. R.H. Hastings, M. Grady, T. Sakuma and M.A. Matthay (1992) Clearance of different-sized proteins from the alveolar space in humans and rabbits. J. Appl. Physiol. 73 1310-1316.
28. J.S. Patton (1996) Mechanisms of macromolecule absorption by the lungs. Adv. Drug Deliv. Rev. 19 3-36.
29. K. Morimoto, H. Yamahara, V.H.L. Lee and K.-J. Kim (1994) Transport of thyrotropin-releasing hormone across rat alveolar epithelial cell monolayers. Life Sci. 54 2083-2092.
30. A. Hussain, J.J. Arnold, M.A. Khan and F. Ahsan (2004) Absorption enhancers in pulmonary protein delivery. J. Control. Release 94 15-24.
31. Y. Fukuda, T. Tsuji, T. Fujita, A. Yamamoto and S. Muranishi (1995) Susceptibility of insulin to proteolysis in rat lung homogenate and its protection from proteolysis by various protease inhibitors. Biol. Pharm. Bull. 18 891-894.
32. K. Okumura, S. Iwakawa, T. Yoshida, T. Seki and F. Komada (1992) Intratracheal delivery of insulin absorption from solution and aerosol by rat lung. Int. J. Pharm 88 63-73.
33. F. Johansson, E. Hjertberg, S. Eirefelt, A. Tronde and U.H. Bengtsson (2002) Mechanisms for absorption enhancement of inhaled insulin by sodium taurocholate. Eur. J. Pharm. Sci. 17 63-71.
34. A. Yamamoto, S. Okumura, Y. Fukuda, M. Fukui, K. Takahashi and S. Muranishi (1997) Improvement of the pulmonary absorption of (Asu1,7)-eel calcitonin by various absorption enhancers and their pulmonary toxicity in rats. J. Pharm. Sci. 86 1144-1147.
35. S. Kobayashi, S. Kondo and K. Juni (1994) Study on pulmonary delivery of salmon calcitonin in rats: Effects of protease inhibitors and absorption enhancers. Pharm. Res. 11 1239-1243.
36. S. Kobayashi, S. Kondo and K. Juni (1996) Pulmonary delivery of salmon calcitonin dry powders containing absorption enhancers in rats. Pharm. Res. 13 80-83.
37. S.-A. Cryan (2005) Carrier-based strategies for targeting protein and peptide drugs to the lungs. AAPS J. 7 E20-E41.
38. F.-Y. Liu, Z. Shao, D.O. Kildsig and A.K. Mitra (1993) Pulmonary delivery of free and liposomal insulin. Pharm. Res. 10 228-232.
39. G.V. Letsou, H.J. Safi, M.J. Reardon, M. Ergenoglu, Z. Li, C.N. Kolonaris, et al. (1999) Pharmacokinetics of liposomal aerosolized cyclosporine A for pulmonary immunosuppression. Ann. Thorac. Surg. 68 2044-2048.
40. C. Khanna, D.E. Hasz, J.S. Klausner and P.M. Anderson (1996) Aerosol delivery of interleukin 2 liposomes is nontoxic and biologically effective: Canine studies. Clin. Cancer Res. 2 721-734.
41. G.D. Griffiths, G.J. Phillips and S.C. Bailey (1999) Comparison of the quality of protection elicited by toxoid and peptide liposomal vaccine formulations against ricin as assessed by markers of inflammation. Vaccine 17 2562-2568.
42. Z. Shao, Y. Li, T. Chermak and A.K. Mitra (1994) Cyclodextrins as mucosal absorption promoters of insulin. II. Effects of β-cyclodextrin derivatives on α-chymotryptic degradation and enteral absorption of insulin in rats. Pharm. Res. 11 1174-1179.
43. A. Hussain, T. Yang, A.-A. Zaghloul and F. Ahsan (2003) Pulmonary absorption of insulin mediated by tetradecyl-β-maltoside and dimethyl-β-cyclodextrin. Pharm. Res. 20 1551-1557.
44. W.T. Cefalu, C.C. Balagtas, W.H. Lanschultz and R.A. Gelfand (2000) Sustained efficacy and pulmonary safety of inhaled insulin during 2-years of outpatient therapy. Diabetes 49 A101.
45. S. Dokka, D. Toledo, X. Shi, V. Castranova and Y. Rojanasakul (2000) Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes. Pharm. Res. 17 521-525.
46. C.J. Bailey and A.H. Barnett (2007) Why is Exubera being withdrawn? Br. Med. J. 335 1156.
47. L. Garcia-Contreras and H.D.C. Smyth (2005) Liquid-spray or dry-powder systems for inhaled delivery of peptide and proteins? Am. J. Drug Deliv. 3 29-45.
48. M.C. Manning, K. Patel and R.T. Borchardt (1989) Stability of protein pharmaceuticals. Pharm. Res. 6 903-918.
49. R.W. Niven and A.J. Hickey (2007) Atomization and nebulizers. A.J. Hickey (Eds) Inhalation Aerosols: Physical and Biological Basis for Therapy New York, USA: Informa Healthcare USA
50. B.J. Greenspan (2007) Ultrasonic and electrohydrodynamic methods for aerosol generation. A.J. Hickey (Eds) Inhalation Aerosols: Physical and Biological Basis for Therapy New York, USA: Informa Healthcare USA
51. D.C. Cipolla, A.R. Clark, H.-K. Chan, I. Gonda and S.J. Shire (1994) Assessment of aerosol delivery systems for recombinant human deoxyribonuclease. STP Pharma. Sci. 4 50-62.
52. T. Arakawa, S.J. Prestrelski, W.C. Kenney and J.F. Carpenter (1993) Factors affecting short-term and long-term stabilities of proteins. Adv. Drug Deliv. Rev. 10 1-28.
53. P.K. Gupta and A.L. Adjei (1997) Therapeutic inhalation aerosols. A.L. Adjei, P.K. Gupta (Eds) Inhalation Delivery of Therapeutic Peptides and Proteins New York, USA: Marcel Dekker 185-234.
54. R.W. Niven, A.Y. Ip, S.D. Mittelman, C. Farrar, T. Arakawa and S.J. Prestrelski (1994) Protein nebulization: I. Stability of lactate dehydrogenase and recombinant granulocyte-colony stimulating factor to air-jet nebulizaion. Int. J. Pharm. 109 17-26.
55. H. Steckel, F. Eskander and K. Witthohn (2003) Effect of excipients on the stability and aerosol performance of nebulised aviscumine. J. Aerosol Med. 16 417-432.
56. H. Steckel, F. Eskander and K. Witthohn (2003) Effect of cryoprotectants on the stability and aerosol performance of nebulized aviscumine, a 57-kDa protein. Eur. J. Pharm. Biopharm. 56 11-21.
57. H. Steckel, F. Eskander and K. Witthohn (2003) The effect of formulation variables on the stability of nebulised aviscumine. Int. J. Pharm. 257 181-194.
58. Pulmozyme® Consumer Medicine Information, Roche Products Pty Ltd, Dee Why, NSW, Australia, 2008.
59. I. Gonda (1997) Deoxyribonuclease inhalation. A.L. Adjei, P.K. Gupta (Eds) Inhalation Delivery of Therapeutic Peptides and Proteins New York, USA: Marcel Dekker 355-365.
60. R. Rubsamen (1997) Novel aerosol peptide drug delivery systems. A.L. Adjei, P.K. Gupta (Eds) Inhalation Delivery of Therapeutic Peptides and Proteins New York, USA: Marcel Dekker 703-731.
61. S. Mudumba, M. Khossravi, D. Yim, T. Rossi, D. Pearce, M. Hughes, et al. (2000) Delivery of rhDNase by the AERx® pulmonary delivery system. R.N. Dalby, P.R. Byron, S. Farr, J. Peart (Eds) Respiratory Drug Delivery VII Raleigh, NC, USA: Serentec Press 329-332.
62. R.R. Henry, S.R.D. Mudaliar, W.C. Howland III, N. Chu, D. Kim, B. An, et al. (2003) Inhaled insulin using the AERx Insulin Diabetes Management System in healthy and asthmatic subjects. Diabetes Care 26 764-769.
63. S. Farr, D. Reynolds, A. Nat, S. Srinivasan, M. Roach, S. Jensen, et al. (2002) Technical development of AERx® Diabetes Management System: Essential characteristics for diabetes treatment with pulmonary insulin. R.N. Dalby, P.R. Byron, J. Peart, S. Farr (Eds) Respiratory Drug Delivery VIII Raleigh, NC, USA: Davis Horwood International 51-60.
64. S. Sangwan, J.M. Agosti, L.A. Bauer, B.A. Otulana, R.J. Morishige, D.C. Cipolla, et al. (2001) Aerosolized protein delivery in asthma: Gamma camera analysis of regional deposition and perfusion. J. Aerosol Med. 14 185-195.
65. T.S. Purewal and D.J.W. Grant (1998) Metered Dose Inhaler Technology. Buffalo Grove, IL, USA: Interpharm Press
66. É.Á. Quinn, R.T. Forbes, A.C. Williams, M.J. Oliver, L. McKenzie and T.S. Purewal (1999) Protein conformational stability in the hydrofluoroalkane propellants tetrafluoroethane and heptafluoropropane analysed by Fourier transform Raman spectroscopy. Int. J. Pharm. 186 31-41.
67. A.R. Brown and D.W. George (1997) Tetrafluoroethane (HFC 134A) propellant-driven aerosols of proteins. Pharm. Res. 14 1542-1547.
68. R.O. Williams III and J. Liu (1998) Formulation of a protein with propellant HFA 134a for aerosol delivery. Eur. J. Pharm. Sci. 7 137-144.
69. M. Hausmann, S. Dellweg, C. Osborn, L. Heinemann, A. Buchwald, R. Rosskamp, et al. (2006) Inhaled insulin as adjunctive therapy in subjects with type 2 diabetes failing oral agents: A controlled proof-of-concept study. Diabetes Obes. Metab. 8 574-580.
70. A.L. Adjei, P. Genova, Y. Zhu, F. Sexton (2006) Method of treating a systemic disease. Patent applicant: KOS Pharmaceuticals, Inc. Publication info: US2004042967 (A1) – 2004–03–04, and US7056494 (B2) – 2006–06–06.
71. G. Brambilla, S. Berrill, R.J. Davies, D. Ganderton, S.C. George, D.A. Lewis, et al. (2003) Formulation of leuprolide as an HFA solution pMDI. J. Aerosol Med. 16 209.
72. N. Islam and E. Gladki (2008) Dry powder inhalers (DPIs) – A review of device reliability and innovation. Int. J. Pharm. 360 1-11.
73. H.-K. Chan and I. Gonda (1998) Solid state characterization of spray-dried powders of recombinant human deoxyribonuclease (rhDNase). J. Pharm. Sci. 87 647-654.
74. A.R. Clark, N. Dasovich, I. Gonda and H.-K. Chan (1996) The balance between biochemical and physical stability for inhalation protein powders: rhDNase as an example. R.N. Dalby, P.R. Byron, S. Farr (Eds) Resiratory Drug Delivery V Buffalo Grove, IL, USA: Interpharm Press 167-174.
75. J.D. Andya, Y.-F. Maa, H.R. Constantino, P.-A. Nguyen, N. Dasovich, T.D. Sweeney, et al. (1999) The effect of formulation excipients on protein stability and aerosol performance of spray-dried powders of a recombinant humanized anti-IgE monoclonal antibody. Pharm. Res. 16 350-358.
76. J.S. Patton, L. Foster, R.M. Platz (1999) Methods and compositions for pulmonary delivery of insulin. Patent Applicant: Nektar Therapeutics. Publication info: JP2006077032 (A) – 2006–03–23.
77. C.P. Quan, S. Wu, N. Dasovich, C. Hsu, T. Patapoff and E. Canova-Davis (1999) Susceptibility of rhDNase I to glycation in the dry-powder state. Anal. Chem. 71 4445-4454.
78. F. Frank (1994) Long-term stabilization of biologicals. Biotechnol. 12 253-256.
79. K.-I. Izutsu, S. Yoshioka and T. Terao (1993) Decreased protein-stabilizing effects of cryoprotectants due to crystallization. Pharm. Res. 10 1232-1237.
80. M.J. Pikal, K.M. Dellerman, M.L. Roy and R.M. Riggin (1991) The effects of formulation variables on the stability of freeze-dried human growth hormone. Pharm. Res. 8 427-436.
81. J.F. Carpenter, S.J. Prestrelski and A. Dong (1998) Application of infrared spectroscopy to development of stable lyophilized protein formulations. Eur. J. Pharm. Biopharm. 45 231-238.
82. M.J. Hageman (1992) Sorption and solid-state stability of proteins. T.J. Ahern, M.C. Manning (Eds) Stability of Protein Pharmaceuticals, Part A: Chemical and Physical Pathways of Protein Degradation New York, USA: Plenum Press 273-309.
83. F. Separovic, Y.H. Lam, X. Ke and H.-K. Chan (1998) A solid-state NMR study of protein hydration and stability. Pharm. Res. 15 1816-1821.
84. H.-K. Chan, K.-L. Au-Yeung and I. Gonda (1999) Development of a mathematical model for the water distribution in freeze-dried solids. Pharm. Res. 16 660-665.
85. Y. Roos and M. Karel (1991) Plasticizing effect of water on thermal behavior and crystallization of amorphous food models. J. Food Sci. 56 38-43.
86. B.C. Hancock, S.L. Shamblin and G. Zografi (1995) Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures. Pharm. Res. 12 799-806.
87. H.-K. Chan, A.R. Clark, J.C. Feeley, M.-C. Kuo, R. Lehrman, K. Pikal-Cleland, et al. (2004) Physical stability of salmon calcitonin spray-dried powders for inhalation. J. Pharm. Sci. 93 792-804.
88. N.Y.K. Chew and H.-K. Chan (2000) Effect of humidity on the dispersion of dry powers. R.N. Dalby, P.R. Byron, S. Farr, J. Peart (Eds) Respiratory Drug Delivery VII Raleigh, NC, USA: Serentec Press 615-618.
89. C. Yamashita, T. Nishibayashi, S. Akashi, H. Toguchi and M. Odomi (1996) A novel formulation of dry powder for inhalation of peptides and proteins. R.N. Dalby, P.R. Byron, S. Farr (Eds) Respiratory Drug Delivery V Buffalo Grove, IL, USA: Interpharm Press 483-486.
90. H.-K. Chan, A. Clark, I. Gonda, M. Mumenthaler and C. Hsu (1997) Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery. Pharm. Res. 14 431-437.
91. D.A. Edwards, J. Hanes, G. Caponetti, J. Hrkach, A. Ben-Jebria, M.L. Eskew, et al. (1997) Large porous particles for pulmonary drug delivery. Science 276 1868-1872.
92. Y.-F. Maa, P.-A. Nguyen, T.D. Sweeney, S.J. Shire and C.C. Hsu (1999) Protein inhalation powders: Spray drying vs spray freeze drying. Pharm. Res. 16 249-254.
93. A.I. Bot, T.E. Tarara, D.J. Smith, S.R. Bot, C.M. Woods and J.G. Weers (2000) Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract. Pharm. Res. 17 275-283.
94. H. Adi, D. Traini, H.-K. Chan and P.M. Young (2008) The influence of drug morphology on the aerosolisation efficiency of dry powder inhaler formulations. J. Pharm. Sci. 97 2780-2788.
95. S. Adi, H. Adi, P. Tang, D. Traini, H.-K. Chan and P.M. Young (2008) Micro-particle corrugation, adhesion and inhalation aerosol efficiency. Eur. J. Pharm. Sci. 35 12-18.
96. N.Y.K. Chew and H.K. Chan (2001) Use of solid corrugated particles to enhance powder aerosol performance. Pharm. Res. 18 1570-1577.
97. N.Y.K. Chew, P. Tang, H.K. Chan and J.A. Raper (2005) How much particle surface corrugation is sufficient to improve aerosol performance of powders? Pharm. Res. 22 148-152.
98. M. Mumenthaler, C.C. Hsu and R. Pearlman (1994) Feasibility study on spray-drying protein pharmaceuticals: Recombinant human growth hormone and tissue-type plasminogen activator. Pharm. Res. 11 12-20.
99. Y.-F. Maa, P.-A.T. Nguyen and S.W. Hsu (1998) Spray-drying of air–liquid interface sensitive recombinant human growth hormone. J. Pharm. Sci. 87 152-159.
100. R. Vanbever, J.D. Mintzes, J. Wang, J. Nice, D. Chen, R. Batycky, et al. (1999) Formulation and physical characeterization of large porous particles for inhalation. Pharm. Res. 16 1735-1742.
101. R.M. Platz, A. Ip, C.L. Whitham (1994) Process for preparing micronized polypeptide drugs. Patent Applicant: Stanford Res Inst Int. Publication info: S5354562 (A) – 1994–10–11.
102. R.T. Bustami, H.-K. Chan, F. Dehghani and N.R. Foster (2000) Generation of micro-particles of proteins for aerosol delivery using high pressure modified carbon dioxide. Pharm. Res. 17 1360-1366.
103. R.T. Bustami, H.-K. Chan and N.R. Foster (2000) Aerosol delivery of protein powders processed by supercritical fluid technology. R.N. Dalby, P.R. Byron, S. Farr, J. Peart (Eds) Respiratory Drug Delivery VII Raleigh, NC, USA: Serentec Press 611-614.
104. R.W. Sievers, S.P. Sellers, K.D. Kusek, G.S. Glark, B.J. Korte, Fine-particle formation using supercritical carbon dioxide-assisted aerosolization and bubble drying, in: Proceedings of the 218th ACS National Meeting, New Orleans, LA, USA, 1999.
105. R. Sloan, H.E. Hollowood, G.O. Hupreys, W. Ashraf, Y. P, Supercritical fluid processing: Preparation of stable protein particles, in: Proceedings of the Fifth Meeting of Supercritical Fluids, Nice, France, 1998.
106. W.J. Glover, E. Wan, J.S. Yun, J. Chen (2009) A process for making micro-sized protein particles. Patent Applicant: Nanomaterials Technology Pte Ltd. Publication info: WO2009020434 (A1) – 2009–02–12.
107. H. Chiou, H.-K. Chan, R.K. Prud'homme and J.A. Raper (2008) Evaluation on the use of the confined liquid impinging jets for the synthesis of nanodrug particles. Drug Dev. Ind. Pharm. 34 59-64.
108. H. Chiou, H.-K. Chan, D. Heng, R.K. Prud'homme and J.A. Raper (2008) A novel production method for inhalable cyclosporine A powders by confined liquid impinging jet precipitation. J. Aerosol Sci. 39 500-509.
109. S.S. Steiner, A. Pfützner, B.R. Wilson, O. Harzer, L. Heinemann and K. Rave (2002) Technosphere/Insulin: Proof of concept study with a new insulin formulation for pulmonary delivery. Exp. Clin. Endocrinol. Diabet. 110 17-21.
110. H. Lian, S.S. Steiner, R.D. Sofia, J.H. Woodhead, H.H. Wolf, H.S. White, et al. (2000) A self-complementary, self-assembling microsphere system: Application for intravenous delivery of the antiepileptic and neuroprotectant compound felbamate. J. Pharm. Sci. 89 867-875.
111. L.R. Brown, J. Rashba-Step, T.L. Scott, Y. Qin, P.W. Rulon, J. McGeehan, et al. (2002) Pulmonary delivery of novel insulin microspheres. R.N. Dalby, P.R. Byron, J. Peart, S. Farr (Eds) Respiratory Drug Delivery VIII Raleigh, NC, USA: Davis Horwood International 431-434.
112. Y.-F. Maa, P.-A. Nguyen, J.D. Andya, N. Dasovich, T.D. Sweeney, S.J. Shire, et al. (1998) Effect of spray drying and subsequent processing conditions on residual moisture content and physical/biochemical stability of protein inhalation powders. Pharm. Res. 15 768-775.
113. Food and Drug Administration, Guidance for industry: Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products. Chemistry, Manufacturing, and Controls Documentation, Food and Drug Administration, Rockville, MD, USA, 1998.